300401.SZ
Zhejiang Garden Biopharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 14.14
−8.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2B | 1.2B | 1.2B | 1.1B | 1.4B |
| Cost of Revenue | 549.6M | 549.1M | 516.8M | 439.3M | 481.3M |
| Gross Profit | 638.3M | 688.3M | 726.5M | 655.3M | 936.3M |
| Operating Expenses | |||||
| R&D Expense | 72.4M | 65.5M | 83.8M | 90.9M | 70.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 94.9M | 97.9M | 115.8M | 127.1M | 112.5M |
| Selling & Marketing Expense | 127.9M | 139.1M | 193.6M | 252.4M | 337.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 353.0M | 352.0M | 435.6M | 500.6M | 535.2M |
| Cost and Expenses | 902.6M | 901.1M | 952.3M | 939.9M | 1.0B |
| Operating Income (EBIT) | 300.5M | 350.0M | 355.4M | 207.1M | 436.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 297.7M | 352.5M | 358.7M | 211.0M | 442.5M |
| Income Tax Expense | 39.0M | 47.6M | 49.5M | 18.7M | 58.8M |
| Bottom Line | |||||
| Net Income | 258.6M | 304.9M | 309.2M | 192.3M | 383.7M |
| Earnings from Cont. Ops | 258.6M | 304.9M | 309.2M | 192.3M | 383.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 258.6M | 304.9M | 309.2M | 192.3M | 383.7M |
| Per Share | |||||
| Basic EPS | CN¥0.47 | CN¥0.56 | CN¥0.57 | CN¥0.35 | CN¥0.70 |
| Diluted EPS | CN¥0.47 | CN¥0.51 | CN¥0.52 | CN¥0.32 | CN¥0.70 |
| Revenue Per Share | CN¥2.13 | CN¥2.27 | CN¥2.29 | CN¥1.99 | CN¥2.59 |
| Shares | |||||
| Basic Shares Outstanding | 558.6M | 544.4M | 542.5M | 549.6M | 548.2M |
| Diluted Shares Outstanding | 558.6M | 544.4M | 542.5M | 549.6M | 548.2M |
| Profitability Metrics | |||||
| EBITDA | — | 528.4M | 511.2M | 340.4M | 497.0M |
| D&A | — | 178.3M | 155.8M | 133.3M | 60.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026